Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Multiple Sclerosis: Update Bulletin [December 2015]

Product Code:
596200526
Publication Date:
December 2015
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in multiple sclerosis (MS): Topics covered include opinions regarding Roche’s ocrelizumab Phase III data in relapsing- remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS); Biogen/AbbVie’s Zinbryta (daclizumab high-yield process) DECIDE study; Sanofi’s Aubagio TEMSO trial and Sanofi’s five-year Lemtrada (alemtuzumab) data. Insights were also sought on the NEDA-4 definition and Alkermes’ ALKS 8700.

Key Questions Answered in this Update Bulletin:

  • How do KOLs view ocrelizumab in RRMS and PPMS?
  • What factors will determine ocrelizumab’s positioning in the treatment algorithm?
  • What are KOLs’ views on Zinbryta’s DECIDE trial?
  • How important are the results from the Aubagio TEMSO study?
  • Are KOLs optimistic regarding Lemtrada’s long-term data?
  • What do KOLs think of the NEDA-4 definition?
  • How clinically attractive is ALKS 8700?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved